Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$8.94 USD

8.94
264,778

+0.19 (2.17%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $8.95 +0.01 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks News

Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 18.75% and 9.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of 4% and 0.62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 11.11% and 24.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of -30% and 1.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ImmunoGen (IMGN) Down 16.6% Since Last Earnings Report: Can It Rebound?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Corcept (CORT) Up 9.6% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance Bio (TBPH) Down 2% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.

Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates

Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.

Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?

Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment of pediatric patients.

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -3.57% and 3.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?

Viatris' (VTRS) Q4 results are likely to be impacted by foreign exchange rate fluctuations. With the Biocon deal closed, investors await its impact on the 2023 guidance.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -26.47% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for February 14th

INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.